Table 2.
Multivariable Survival Analyses of the Association of Time-Varying Persistency and Clinical Events (Immunologic Failure, Oportunistic Infection/Malignancy, Death) Among Treatment-Naive Individuals Starting Antiretroviral Therapy 1/1/2000–5/11/2011 at the UAB 1917 HIV/AIDS Clinic Cohort
| Characteristic | Immunologic failure HR (95% CI) | OI/malignancy HR (95% CI) | Death HR (95% CI) |
|---|---|---|---|
| Persistency (per 180 days)a,b | 0.84 (0.70–1.00) | 0.91 (0.80–1.03) | 0.95 (0.87–1.04) |
| Age at ART initiation (years) | |||
| 19–29 | 0.96 (0.59–1.55) | 0.56 (0.24–1.29) | 0.61 (0.30–1.27) |
| 30–39 | 0.71 (0.44–1.12) | 0.58 (0.29–1.14) | 0.48 (0.25–0.93) |
| 40–49 | 0.70 (0.44–1.11) | 0.79 (0.41–1.51) | 0.69 (0.37–1.28) |
| ≥50 | 1.0 | 1.0 | 1.0 |
| Race | |||
| White | 1.0 | 1.0 | 1.0 |
| Nonwhite | 0.89 (0.64–1.24) | 1.03 (0.60–1.76) | 1.60 (0.93–2.76) |
| Gender | |||
| Male | 1.0 | 1.0 | 1.0 |
| Female | 1.24 (0.84–1.84) | 0.77 (0.41–1.46) | 0.60 (0.33–1.09) |
| Insurance | |||
| Private | 1.0 | 1.0 | 1.0 |
| Public | 1.06 (0.71–1.60) | 1.07 (0.61–1.88) | 2.91 (1.65–5.14) |
| Uninsured | 1.01 (0.70–1.46) | 0.84 (0.45–1.59) | 1.25 (0.65–2.41) |
| Schizophrenia | |||
| No | 1.0 | 1.0 | 1.0 |
| Yes | 2.11 (1.10–4.05) | 1.48 (0.42–5.17) | 2.72 (1.05–7.02) |
| Affective mental health disorder | |||
| No | 1.0 | 1.0 | 1.0 |
| Yes | 1.30 (0.95–1.79) | 1.08 (0.66–1.77) | 0.53 (0.33–0.85) |
| Baseline CD4 (cells/mm3) | |||
| <200 | — | 2.14 (0.96–4.77) | 3.68 (1.27–10.65) |
| 200–350 | 0.84 (0.34–2.11) | 2.42 (0.80–7.31) | |
| >350 | 1.0 | 1.0 | |
| Baseline log10 VL median (IQR) | 0.62 (0.52–0.75) | 1.19 (0.84–1.71) | 0.98 (0.71–1.35) |
| ART start | |||
| 2000–2003 | 1.0 | 1.0 | 1.0 |
| 2004–2006 | 1.39 (0.85–2.27) | 0.67 (0.37–1.22) | 1.34 (0.73–2.46) |
| 2007–2010 | 1.43 (0.89–2.30) | 0.51 (0.26–0.98) | 0.82 (0.38–1.77) |
| Third drug | |||
| NNRTI | 1.0 | 1.0 | 1.0 |
| II | 0.99 (0.42–2.33) | 1.70 (0.39–7.49) | 4.17 (0.91–19.24) |
| NRTI | 1.66 (0.87–3.19) | 1.24 (0.49–3.12) | 1.90 (0.89–4.07) |
| PI | 1.57 (1.09–2.26) | 1.24 (0.68–2.28) | 0.58–2.02) |
p-values for persistency: immunologic failure 0.0454; OI/malignancy 0.1236; death 0.2808.
Persistency/time interaction term results. [Results in bold are significant (p-value<0.05) while results marked with asterisks are marginally significant (0.05<p-value<0.10).] Immunologic failure: Persistency (per 180 days) early (<365 days): 0.66; 0.31–1.39. Persistency (per 180 days) late (>365 days): 0.85; 0.72–1.00. Incident malignancy/OI: Persistency (per 180 days) early (<365 days): 1.04; 0.25–4.28. Persistency (per 180 days) early (>365 days): 0.90; 0.80–1.02*. Death: Persistency (per 180 days) early (<365 days): 0.42; 0.17–1.06*. Persistency (per 180 days) early (>365 days): 0.97; 0.89–1.05.
OI, oportunistic infection; HR, hazard ratio; CI, confidence interval.